VidPrevtyn Beta (COVID-19 Vaccine (recombinant, adjuvanted))
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- COVID-19 Vaccine (recombinant, adjuvanted)
- Company
- Sanofi Pasteur
- Status
- Withdrawn
- Therapeutic area
- COVID-19 virus infection
- CHMP opinion
- Thu 10 Nov 2022
- EU approval
- Thu 10 Nov 2022
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005754
- ATC
- J07BN04
- Official record
- www.ema.europa.eu
Indication
VidPrevtyn Beta is indicated as a booster for active immunisation to prevent COVID-19 in adults who have previously received an mRNA or adenoviral vector COVID-19 vaccine (see sections 4.2 and 5.1 in product information document). The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Bimervax Authorised · Hipra Human Health S.L.
- 🇪🇺 Nuvaxovid Authorised · Sanofi Winthrop Industrie
Follow VidPrevtyn Beta
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.